Abstracts tagged "Myositis"

Abstract Number: 2515 • ACR Convergence 2023
Machine Learning-Based Stratification of Mixed Connective Tissue Disease Using Immunophenotyping Data from Patients with Related Autoimmune Diseases
Shinji Izuka¹, Toshihiko Komai¹, Takahiro Itamiya¹, Mineto Ota², Saeko Yamada¹, Yasuo Nagafuchi², Hirofumi Shoda¹, Kosuke Matsuki³, Kazuhiko Yamamoto⁴, Tomohisa Okamura⁵ and Keishi Fujio¹, ¹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ²Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan, ³Research Division, Chugai Pharmaceutical Co., Ltd., Yokohama City, Japan, ⁴Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan, ⁵Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Department of Functional Genomics and Immunological Diseases, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
Background/Purpose: Mixed connective tissue disease (MCTD) is a heterogenous autoimmune disorder with overlapping clinical features of systemic lupus erythematosus (SLE), polymyositis/dermatomyositis, and systemic sclerosis (SSc).…
Abstract Number: 0169 • ACR Convergence 2023
Added Value of Anti-HMGCR and Anti-SRP Antibodies in the Diagnosis of Immune Mediated Necrotizing Myopathy: An Outcome and Cost Comparison from the USA Perspective
Alejandro Figueroa-Lara¹, Mary Ann Aure² and Carmen Andalucia¹, ¹Werfen, San Diego, CA, ²Werfen, Chula Vista, CA
Background/Purpose: Immune-mediated necrotizing myopathies (IMNM) is a subgroup of immune-mediated myopathies (IMM). The diagnosis of IMNM relied on the presence of proximal muscle weakness, high…
Abstract Number: 0304 • ACR Convergence 2023
Incidence of Disease Flares Following COVID-19 Vaccination in a Diverse Idiopathic Inflammatory Myopathy Cohort
Hillary Weisleder¹, Ana Valle¹, Xianhong Xie² and Shereen Mahmood³, ¹Montefiore Medical Center, Bronx, NY, ²Albert Einstein College of Medicine, Bronx, NY, ³Albert Einstein College of Medicine / Montefiore Medical Center, New York, NY
Background/Purpose: Autoimmune activation in the setting of vaccination against coronavirus disease 2019 (COVID-19) is a well-documented phenomenon in the medical literature. For patients with idiopathic…
Abstract Number: 1161 • ACR Convergence 2023
Proteasome Inhibitor Repurposed for Dermatomyositis: Results of a Drug Repurposing Analysis Based on the Transcriptomic Signature of Patients’ Perifascicular Fibers Validated in Pre-clinical Models
Léa Debrut¹, Margherita Giannini², Céline Keime¹, Daniela Rovito¹, Béatrice Lannes³, Anne-Laure Charles⁴, Daniel Metzger¹, Bernard Geny⁵, Gilles Laverny¹ and Alain Meyer⁶, ¹Institut de Génétique et de Biologie Moléculaire et Cellulaire (IGBMC), Illkirch, France, ²Nouvel Hopital Civil, Strasbourg, Strasbourg, France, ³Hôpital de Hautepierre - Hôpitaux Universitaires de Strasbourg, Strasbourg, France, ⁴UR3072, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France, ⁵Nouvel Hôpital Civil, Strasbourg, France, ⁶Hôpitaux Universitaires de Strasbourg, Strasbourg, France
Background/Purpose: Dermatomyositis (DM) is an autoimmune myopathy responsible for muscle weakness associated with decreased quality of life and increased mortality. DM muscular histology is characterized…
Abstract Number: 1246 • ACR Convergence 2023
Assessment and Outcomes of 63 Cases of Juvenile Dermatomyositis-Associated Calcinosis
Belina Yi¹, Dawn Wahezi², Lauren Covert³, Kaveh Ardalan⁴, Joyce Hui-Yuen⁵, Natalia Vasquez Canizares⁶, Doaa Mosad Mosa⁷, Madison Jones⁸, Colleen Correll⁹, Alexis Begezda¹⁰, Susan Shenoi¹¹, Eveline Wu¹², Leonard Kovalick¹³, William Lapin¹⁴, Stacey Tarvin¹⁵, Melissa Oliver¹⁶, Martha Rodriguez¹⁷, Itay Marmor¹⁸, Kevin Baszis¹⁹, Alysha Taxter²⁰, Andrew Hanson²¹, Cynthia Crowson²² and Amir Orandi²², ¹Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital at Montefiore, New Rochelle, NY, ³Duke University, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵North Shore LIJ Health System, Great Neck, NY, ⁶Children's Hospital at Montefiore, New York, NY, ⁷Mansoura University Hospitals, Mansoura University Faculty of Medicine, Mansoura city, Egypt, ⁸Keck School of Medicine of University of Southern California, Los Angeles, CA, ⁹University of Minnesota, Minneapolis, MN, ¹⁰Penn State, Hummelstown, PA, ¹¹Seattle Childrens Hospital, Mercer Island, WA, ¹²University of North Carolina School of Medicine, Chapel Hill, NC, ¹³UNC Health Care, Durham, NC, ¹⁴Connecticut Children's, Hartford, CT, ¹⁵Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ¹⁶Indiana University, Indianapolis, IN, ¹⁷Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁸Dana-Dwek Children's Hospital, Hod Hasharon, Israel, ¹⁹Washington Univ in St. Louis School of Medicine, St. Louis, MO, ²⁰Nationwide Children's, Columbus, OH, ²¹Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ²²Mayo Clinic, Rochester, MN
Background/Purpose: Calcinosis is a poorly understood and morbid complication of juvenile dermatomyositis (JDM). As there is no consensus treatment approach for calcinosis, and limited knowledge…
Abstract Number: 1961 • ACR Convergence 2023
Anti-PM/Scl Autoantibodies in Juvenile Myositis Are Associated with a Distinct Phenotype Resembling Anti-synthetase Syndrome
Matthew Sherman¹, Payam Noroozi Farhad², Edward Trieu³, Katherine Pak⁴, Iago Pinal-Fernandez⁴, Kakali Sarkar², Megan Neely⁵, Ira Targoff⁶, Frederick Miller⁷, Andrew Mammen⁸ and Lisa Rider⁹, ¹NIAMS/NIH, Washington, DC, ²Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, ³Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴National Institutes of Health, Bethesda, MD, ⁵Department of Biostatistics and Bioinformatics, Duke University, Durham, NC, ⁶Veterans Affairs Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁷NIH, NIEHS, Chapel Hill, NC, ⁸NIH, Bethesda, MD, ⁹NIEHS, NIH, Bethesda, MD
Background/Purpose: Anti-PM/Scl autoantibodies (Abs) are an uncommon myositis-associated autoantibody (MAA) in juvenile myositis. The clinical features and outcomes associated with anti-PM/Scl Abs in juvenile myositis…
Abstract Number: 2575 • ACR Convergence 2023
Accurate Stratification of Cancer Risk in a Real-World Cohort Using the International Guideline for Idiopathic Inflammatory Myopathy-Associated Cancer Screening
Alexander Oldroyd¹, Francisca Bozan¹, Xia Lyu², Patrick Gordon³, David Isenberg⁴, Neil McHugh⁵, Harsha Gunawardena⁶, Patrick Kiely⁷, Janine Lamb¹, Pedro Machado⁸, James Miller⁹, Sarah Tansley⁵ and Hector Chinoy¹⁰, ¹University of Manchester, Manchester, United Kingdom, ²Department of Rheumatology, Shanghai Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China, ³NHS, London, United Kingdom, ⁴University College London, London, United Kingdom, ⁵University of Bath, Bath, United Kingdom, ⁶North Bristol NHS Trust, Bristol, United Kingdom, ⁷St George’s University Hospitals NHS Foundation Trust, London, United Kingdom, ⁸Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, UK. Department of Rheumatology, Northwick Park Hospital, London North West University Healthcare NHS trust, London, UK., London, United Kingdom, ⁹Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, United Kingdom, ¹⁰The University of Manchester, Sale, United Kingdom
Background/Purpose: Adult-onset idiopathic inflammatory myopathy (IIM) is associated with an increased cancer risk within three years prior to or following IIM onset. The International Guideline…
Abstract Number: 0283 • ACR Convergence 2023
Transcriptomic Profiles in Muscle Biopsies from Systemic Sclerosis Patients with Different Autoantibodies
Maria Casal-Dominguez¹, Jose Cesar Milisenda², Iago Pinal-Fernandez¹, Katherine Pak³, Sandra Muñoz-Braceras¹, Jose Jiram Torres-Ruiz¹, Stefania Dell´Orso⁴, Faiza Naz⁴, Gustavo Gutierrez-Cruz⁴, Shamima Islam¹, Yaiza Duque-Jaimez², Ana Matas-Garcia², Francesc J Garcia-Garcia², Mariona Guitart-Manpel², Gloria Garrabou², Ernesto Trallero-Araguas⁵, Brian Wallit⁶, Lisa Christopher-Stine⁷, Tom Lloyd⁸, Alfredo Guillen-Del-Castillo⁹, Carmen Pilar Simeon-Aznar¹⁰, Josep Maria Grau², Albert Selva-O’Callaghan⁵ and Andrew Mammen¹¹, ¹Muscle Disease Unit, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ²Muscle Research Unit, Internal Medicine Service, Hospital Clinic, Barcelona, Spain, ³National Institutes of Health, Bethesda, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, ⁵Systemic Autoimmune Disease Unit, Vall d’Hebron Institute of Research, Barcelona, Spain, ⁶National Institute of Neurological Diseases and Stroke, National Institutes of Health, Bethesda, MD, ⁷Johns Hopkins University, Baltimore, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD, ⁹Unit of Autoimmune Diseases, Department of Internal Medicine, Hospital Universitario Vall d'Hebron, Barcelona, Spain, ¹⁰Department of Internal Medicine, Systemic Autoimmune Diseases Unit, Hospital Universitario Vall d'Hebronh, Barcelona, Spain, ¹¹NIH, Bethesda, MD
Background/Purpose: The inflammatory myopathies (IM) include dermatomyositis (DM), antisynthetase syndrome (AS), immune-mediated necrotizing myopathy (IMNM), inclusion body myositis (IBM), and overlap myositis (OM), in which…
Abstract Number: 0305 • ACR Convergence 2023
Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome
Javier Narvaez¹, Paola Vidal-Montal², Elena Cañadillas-Sanchez³, Pol Maymó², Judith Palacios², Martí Aguilar², Montserrat Roig² and Joan Miquel Nolla², ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Background/Purpose: Antisynthetase syndrome (ASSD) is a systemic autoimmune condition characterized by the positivity of anti-aminoacyl-transfer-RNA synthetases antibodies (ARS) and the occurrence of the classic triad,…
Abstract Number: 1162 • ACR Convergence 2023
Serial Imaging Changes in Skeletal Muscle Composition and Their Association with Clinical Outcomes in Idiopathic Inflammatory Myopathies
Mamatha Gorijavolu¹, Chengappa Kavadichanda¹, Ramesh Ananthakrishnan¹, Christina Mariaselvam¹, Molly Thabah¹ and VS Negi², ¹Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India, ²All India Institute of Medical Sciences, Bilaspur, Puducherry, India
Background/Purpose: Muscle weakness in inflammatory myopathies (IIM) is due to muscle-edema, atrophy and fatty-infiltration among which edema is the predominant cause at baseline. Some IIM…
Abstract Number: 1255 • ACR Convergence 2023
Clinical Characteristics and Disease Outcomes of anti-NXP2 Positive Juvenile Dermatomyositis: A Single Center Cohort
Sarah Molina¹, Dawn Gist², Marietta De Guzman³, Eyal Muscal⁴, Jamie Lai² and Maria Pereira³, ¹Baylor College of Medicine - Pediatrics Residency Program, Houston, TX, ²Baylor College of Medicine / Texas Children's Hospital, Houston, TX, ³Baylor College of Medicine, Houston, TX, ⁴Division of Rheumatology, Department of Pediatrics, Baylor College of Medicine, Houston, TX
Background/Purpose: Juvenile dermatomyositis (JDM) is a rare idiopathic inflammatory myopathy with clinically heterogeneous presentations that can be categorized by myositis-specific antibodies (MSAs). NXP2 is among…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 2576 • ACR Convergence 2023
Rapid Onset of Response in Adult Dermatomyositis Patients Receiving Anti-interferon β (PF-06823859): Results of a Phase 2, Double-blind, Randomized, Placebo-Controlled Study
Rohit Aggarwal¹, Elena Peeva², Aaron Mangold³, Abigail Sloan² and Myron Chu², ¹University of Pittsburgh, Pittsburgh, PA, ²Pfizer, Cambridge, MA, ³Mayo Clinic, Scottsdale, AZ
Background/Purpose: Interferon (IFN) dysregulation is a key feature in the pathogenesis of Dermatomyositis (DM). PF-06823859 is a potent, selective, humanized IgG1 neutralizing antibody directed against…
Abstract Number: 0284 • ACR Convergence 2023
Phenotyping Calcinosis: A Rare Manifestation of Rare Diseases
Michele Diomedi¹, Federico Fattorini¹, Simone Barsotti², Elenia Laurino¹, Chiara Cardelli¹, Linda Carli¹ and Marta Mosca¹, ¹Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy, ²Internal Medicine, Ospedale di Livorno, Pisa, Italy
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are rare systemic autoimmune disorders, with a pleiotropic clinical picture, specifically characterized from the inflammatory involvement of striate muscles. Calcinosis…
Abstract Number: 0306 • ACR Convergence 2023
Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy
Akanksha Sharma¹, shiri keret², Raisa Lomanto Silva³, Tanya Chandra⁴, Joel Levin⁵, Siamak Moghadam-Kia³, Chester V. Oddis⁶ and Rohit Aggarwal⁶, ¹UPMC Mercy Hospital, Pittsburgh, PA, ²Bnai Zion, Atlit, Israel, ³University of Pittsburgh Medical Center, Pittsburgh, PA, ⁴Georgetown University Hospital, Washington, DC, ⁵University of Pittsburgh, Katz Graduate School, Pittsburgh, PA, ⁶University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIM, myositis) are a systemic autoimmune disease leading to debilitating muscle weakness and significant limitations in daily activities. Physical activity monitor…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].